Abstract：
OBJECTIVE: Women with gynecologic cancers often experience functional impairments impacting quality of life. Physical and occupational therapy (PT/OT) treat functional impairment; however, the acceptability and impact of these services for women with gynecologic cancer are unknown.
METHODS: We reviewed rehabilitation charts of women with gynecologic cancer who received PT/OT (i.e., patients) in 2019 and completed patient-reported outcome measures (PROMs) selected by their therapist at intake (pre) and discharge (post). We calculated descriptive statistics for patient, rehabilitation, and acceptability (0-10) data. For PROM data, we used paired samples t-tests to evaluate pre-post change, and then calculated effect size (Hedge\'s g) and the proportion who achieved a minimal detectable change (MDC).
RESULTS: PT/OT patients (N = 84) were 64.63 ± 11.04 years old with predominant diagnoses of ovarian (41.7%) or endometrial (32.1%) cancer. They attended a median of 13 sessions (IQR = 8.0-19.0). Sessions were predominantly PT (86%) vs. OT (14%). Median acceptability was 10 (IQR = 9.8-10.0). Pre-post improvement was observed for each of the 17 PROMs used by therapists. Significant improvement (p < .05) was observed for four PROMs: the Patient-Specific Functional Scale (M∆ = 2.93 ± 2.31, g = 1.47, 71% achieved MDC), the Lower Extremity Functional Scale (M∆ = 12.88 ± 12.31, g = 0.61, 60% achieved MDC), the Lymphedema Life Impact Scale (M∆ = 20.50 ± 20.61, g = 1.18, 58% achieved MDC), and the Modified Fatigue Impact Scale (M∆ = 6.55 ± 9.69, g = 0.33, 7% achieved MDC).
CONCLUSIONS: PT/OT was acceptable and improved patient-reported outcomes for women with gynecologic cancers. Future research is needed to establish gynecologic-specific guidelines for referral and PT/OT practice.
METHODS: We reviewed rehabilitation charts of women with gynecologic cancer who received PT/OT (i.e., patients) in 2019 and completed patient-reported outcome measures (PROMs) selected by their therapist at intake (pre) and discharge (post). We calculated descriptive statistics for patient, rehabilitation, and acceptability (0-10) data. For PROM data, we used paired samples t-tests to evaluate pre-post change, and then calculated effect size (Hedge\'s g) and the proportion who achieved a minimal detectable change (MDC).
RESULTS: PT/OT patients (N = 84) were 64.63 ± 11.04 years old with predominant diagnoses of ovarian (41.7%) or endometrial (32.1%) cancer. They attended a median of 13 sessions (IQR = 8.0-19.0). Sessions were predominantly PT (86%) vs. OT (14%). Median acceptability was 10 (IQR = 9.8-10.0). Pre-post improvement was observed for each of the 17 PROMs used by therapists. Significant improvement (p < .05) was observed for four PROMs: the Patient-Specific Functional Scale (M∆ = 2.93 ± 2.31, g = 1.47, 71% achieved MDC), the Lower Extremity Functional Scale (M∆ = 12.88 ± 12.31, g = 0.61, 60% achieved MDC), the Lymphedema Life Impact Scale (M∆ = 20.50 ± 20.61, g = 1.18, 58% achieved MDC), and the Modified Fatigue Impact Scale (M∆ = 6.55 ± 9.69, g = 0.33, 7% achieved MDC).
CONCLUSIONS: PT/OT was acceptable and improved patient-reported outcomes for women with gynecologic cancers. Future research is needed to establish gynecologic-specific guidelines for referral and PT/OT practice.
摘要：
目标：患有妇科癌症的妇女经常经历影响生活质量的功能损害。物理和职业治疗（PT/OT）治疗功能损害;然而，这些服务对妇科癌症患者的可接受性和影响尚不清楚.
方法：我们回顾了接受PT/OT（即，患者）在2019年，并完成了其治疗师在摄入（前）和出院（后）时选择的患者报告结果测量（PROM）。我们计算了患者的描述性统计数据，康复,和可接受性(0-10)数据。对于PROM数据，我们使用配对样本t检验来评估后变化前，然后计算效应大小(Hedge\sg)和实现最小可检测变化(MDC)的比例。
结果：PT/OT患者（N=84）为64.63±11.04岁，主要诊断为卵巢癌（41.7％）或子宫内膜癌（32.1％）。他们参加了13次会议（IQR=8.0-19.0）。会议主要是PT（86％）与OT（14%）。中位可接受性为10（IQR=9.8-10.0）。对于治疗师使用的17种PROM中的每一种观察到了pre-post改善。四个PROM的显着改善（p<.05）：患者特定功能量表（MΔ=2.93±2.31，g=1.47，MDC达到71％），下肢功能量表(M÷=12.88±12.31，g=0.61，60%达到MDC)，淋巴水肿寿命影响量表(M÷=20.50±20.61，g=1.18，MDC达到58%)，和修正后的疲劳冲击量表(M÷=6.55±9.69，g=0.33，7%达到MDC)。
结论：PT/OT是可以接受的，并且改善了患者报告的妇科癌症患者的预后。需要进一步的研究来建立针对转诊和PT/OT实践的妇科特定指南。
方法：我们回顾了接受PT/OT（即，患者）在2019年，并完成了其治疗师在摄入（前）和出院（后）时选择的患者报告结果测量（PROM）。我们计算了患者的描述性统计数据，康复,和可接受性(0-10)数据。对于PROM数据，我们使用配对样本t检验来评估后变化前，然后计算效应大小(Hedge\sg)和实现最小可检测变化(MDC)的比例。
结果：PT/OT患者（N=84）为64.63±11.04岁，主要诊断为卵巢癌（41.7％）或子宫内膜癌（32.1％）。他们参加了13次会议（IQR=8.0-19.0）。会议主要是PT（86％）与OT（14%）。中位可接受性为10（IQR=9.8-10.0）。对于治疗师使用的17种PROM中的每一种观察到了pre-post改善。四个PROM的显着改善（p<.05）：患者特定功能量表（MΔ=2.93±2.31，g=1.47，MDC达到71％），下肢功能量表(M÷=12.88±12.31，g=0.61，60%达到MDC)，淋巴水肿寿命影响量表(M÷=20.50±20.61，g=1.18，MDC达到58%)，和修正后的疲劳冲击量表(M÷=6.55±9.69，g=0.33，7%达到MDC)。
结论：PT/OT是可以接受的，并且改善了患者报告的妇科癌症患者的预后。需要进一步的研究来建立针对转诊和PT/OT实践的妇科特定指南。
